Phaseline

Targets › TEC

TEC (Tyrosine-protein kinase Tec): drug programs, companies and trials

2 programs from 2 companies in 19 trials: 10 Phase 3, 9 Phase 2; Immunology, Metabolic and endocrine; next expected readout Dec 2026.

Non-receptor tyrosine kinase that contributes to signaling from many receptors and participates as a signal transducer in multiple downstream pathways, including regulation of the actin cytoskeleton. Plays a redundant role to ITK in regulation of the adaptive immune response. (UniProt, P42680)

Open in Phaseline: the race on TEC, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PfizerRitlecitinib
Tyrosine-protein kinase JAK3 inhibitor; TEC family kinase inhibitor
JAK3, ITK, BMX, TEC, TXKPhase 3Severe Alopecia Areata; Vitiligo; Stable Nonsegmental Vitiligo; Alopecia Areata …Dec 2026
TakedaZasocitinib
TEC kinase inhibitor
TEC, ZAP70Phase 3Psoriatic Arthritis; Plaque Psoriasis; Hidradenitis Suppurativa; Nonsegmental Vitiligo …Feb 2027

Conditions

Psoriatic Arthritis (3) Hidradenitis Suppurativa (2) Crohn's Disease (2) Severe Alopecia Areata (2) Vitiligo (2) Alopecia Areata (2) Plaque Psoriasis (1) Nonsegmental Vitiligo (1) Stable Nonsegmental Vitiligo (1) Chronic Spontaneous Urticaria (1) Keloid (1) Diabetes Mellitus, Type 1 (1)

Modalities

small molecule (2)

Companies

Takeda (1) Pfizer (1)

Related targets

ZAP70 (1) JAK3 (1) ITK (1) BMX (1) TXK (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.